Atara Biotherapeutics Files 8-K Report
Ticker: ATRA · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits
Related Tickers: ATRA
TL;DR
ATRA filed an 8-K with financial statements and exhibits - check for updates.
AI Summary
On July 17, 2024, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operational activities. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing indicates Atara Biotherapeutics is providing updated financial statements and exhibits, which could contain important information for investors regarding the company's financial position.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant negative or positive events.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- July 17, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36548 (identifier) — Commission File Number
- 46-0920988 (identifier) — IRS Employer Identification No.
- 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320 (address) — Principal Executive Offices
- (805) 623-4211 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Atara Biotherapeutics?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of July 17, 2024.
When was this 8-K report filed by Atara Biotherapeutics?
This 8-K report was filed on July 17, 2024.
What is Atara Biotherapeutics, Inc.'s state of incorporation?
Atara Biotherapeutics, Inc. is incorporated in Delaware.
What is the address of Atara Biotherapeutics' principal executive offices?
The address of Atara Biotherapeutics' principal executive offices is 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320.
What is the Commission File Number for Atara Biotherapeutics?
The Commission File Number for Atara Biotherapeutics is 001-36548.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-07-17 16:16:02
Key Financial Figures
- $0.0001 — ich Registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
Filing Documents
- d868530d8k.htm (8-K) — 25KB
- d868530dex991.htm (EX-99.1) — 12KB
- 0001193125-24-180371.txt ( ) — 162KB
- atra-20240717.xsd (EX-101.SCH) — 3KB
- atra-20240717_lab.xml (EX-101.LAB) — 18KB
- atra-20240717_pre.xml (EX-101.PRE) — 11KB
- d868530d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated July 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: July 17, 2024 By: /s/ Eric Hyllengren Eric Hyllengren Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)